Drugs / Serogroup B meningococal vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06832514 | Jan 2025 → Jul 2026 overdue | meningococcal meningitis | University Ghent | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Serogroup B meningococal vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06832514 ↗ |
| Modality | Vaccine | “four-component meningococcal serogroup B (4CMenB; Bexsero®) vaccine” NCT06832514 ↗ |
| Route | Intramuscular | “administered via two intramuscular (IM) injections” NCT06832514 ↗ |